British Business Bank commits over £1B to life sciences

The British Business Bank has surpassed £1 billion in cumulative support for the U.K. life sciences sector, reaching £1.13 billion (€1.36 billion) through commitments to specialist investment funds and direct investments in biotech and medtech companies.

ADVERTISEMENT

Why it matters: The milestone highlights the growing role of public capital in addressing the U.K.’s life sciences funding gap, particularly as companies move into expensive clinical development programs and need larger financing rounds to scale.

The government-owned development bank has spent more than a decade supporting the sector, both by investing directly in companies and by providing capital to venture capital funds that can attract additional private investors.

By the numbers: The Bank’s £1.13 billion in backing is divided between two main activities:

  • £832 million (€999 million) committed to 20 specialist life sciences funds, which the Bank says have attracted another £3.1 billion (€3.72 billion) in private capital.
  • £302 million (€363 million) invested directly in 28 life sciences companies since 2021, half of them university spinouts.

The total includes commitments to investment funds, meaning not all the capital has necessarily been deployed into companies.

Zoom in: Recent investments illustrate the Bank’s approach. It committed £25 million (€30 million) to antibody developer Alchemab Therapeutics, its largest direct life sciences investment to date, and £15 million (€18 million) to Cambridge spinout T-Therapeutics.

Among its fund commitments are £135 million (€162 million) across two Advent Life Sciences funds and £100 million (€120 million) to Apposite Healthcare Growth I.

The track record: Several companies backed by the Bank have subsequently been acquired by international groups. MSD bought EyeBio in 2024 in a deal worth up to $3 billion, while Terumo acquired OrganOx for $1.5 billion in 2025. More recently, Novartis agreed to acquire Imperial College London and the Francis Crick Institute spinout Myricx Bio for up to $1.5 billion.

“Our scientific strength is a major investment opportunity, but realising that potential requires deep pools of capital through years of development,” said Leandros Kalisperas, chief investment officer at the British Business Bank.

Beyond the U.K.: The Bank’s influence also extends to European venture capital firms. Alongside its latest figures, it announced a €58 million commitment to Paris-based Sofinnova Partners’ new €725 million Crossover II fund, which targets around 15 late-stage life sciences companies, primarily in Europe.

The Bank had already committed €30 million to Sofinnova’s €650 million Capital XI fund in 2025. Its combined backing for the French investment manager now totals €88 million.

Between the lines: Such investments allow public institutions to support internationally operating VC managers while seeking to channel capital toward their domestic markets.

A life sciences investor speaking anonymously to European Biotechnology at BIO-Europe explained that public institutions often attach geographic investment requirements to their commitments. A 2023 evaluation of the British Business Bank’s British Patient Capital program confirms that it has used such requirements in the past. However, it remains unclear whether similar conditions apply to Sofinnova’s new fund.

Bottom line: With more than £1 billion committed or invested, the British Business Bank has become a significant source of capital for U.K. life sciences. Its growing network of investments in European VC funds also illustrates how national public funding can shape the broader European investment ecosystem.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!